Harmony Biosciences Holdings (HRMY) Total Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings has reported Total Current Liabilities for 8 years, with the latest figure at $217.3 million in Q1 2026.

• Quarterly Total Current Liabilities rose 24.11% year-over-year to $217.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.3 million (up 24.11% YoY) and the FY2025 annual result came in at $252.1 million, up 44.01% from the prior year.
• Total Current Liabilities fell to $217.3 million in Q1 2026 per HRMY's latest filing, from $252.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $252.1 million in Q4 2025 and troughed at $56.5 million in Q1 2022.
• A 5-year average of $144.0 million and a median of $154.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 125.43% in 2022, then increased 4.7% in 2023.
• Over 5 years, Total Current Liabilities stood at $78.9 million in 2022, then soared by 107.62% to $163.8 million in 2023, then grew by 6.9% to $175.1 million in 2024, then soared by 44.01% to $252.1 million in 2025, then slipped by 13.8% to $217.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $217.3 million, $252.1 million, and $223.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.